Inflammation responses occur under the normal conditions when tissues are damaged by bacteria, toxins, trauma, heat, or any other reason. These response occurs chronic autoimmune and inflammation disorders, including neurodegenerative disease, asthma, psoriasis, cancer, rheumatoid arthritis diabetes, and multiple sclerosis The immunotherapeutic aptitude of these anti-inflammatory peptides (AIPs) has various clinical applications such as in the generation of regulatory T cells and inhibition of antigen-specific T(H)1-driven responses. Moreover, certain synthetic of AIPs act as effective therapeutic agents for autoimmune and inflammatory disorders. The following Figure shows some representative members of AIPs.
Recently, numerous inflammatory diseases and autoimmune disorders by therapeutic peptides has received substantial consideration; however, the prediction of anti-inflammatory peptides via experimental system is often time consuming and expensive task. The development of novel in silico predictors is desired to classify potential anti-inflammatory peptides prior to in vitro investigation. Herein, a novel predictor, called PreAIP (Prediction of Anti-Inflammatory Peptides) was developed.